<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139833">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01280578</url>
  </required_header>
  <id_info>
    <org_study_id>RESPONDER</org_study_id>
    <nct_id>NCT01280578</nct_id>
  </id_info>
  <brief_title>The Coherex FlatStent™ EF PFO Migraine Registry</brief_title>
  <official_title>The Coherex PFO Migraine Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coherex Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coherex Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, single arm, multicenter clinical registry evaluating the change in migraine
      headaches in migraine with aura patients who undergo patent foramen ovale (PFO) closure with
      the Coherex FlatStent™ EF PFO Closure System.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>February 2011</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy</measure>
    <description>Percentage of subjects treated with the FlatStent EF who, achieve a clinically significant reduction in migraine or probable migraine headache days at follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Closure efficacy</measure>
    <description>Degree of closure of PFO at follow-up</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Patients With Migraine and PFO</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter PFO Closure</intervention_name>
    <description>Transcatheter PFO Closure</description>
    <other_name>Coherex FlatStent™ EF PFO Closure System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:

        Age 18-65 males and non pregnant females History of refractory migraine Documented PFO

        Major Exclusion Criteria:

        Known allergy to aspirin or nickel. Medication Overuse Headache Body mass index &gt; 40.
        Recent Botulinum neurotoxin type A treatment Other known structural heart disease,
        coronary artery disease, atrial fibrillation PFO morphology not suitable for FlatStent EF
        Patients who have had a stroke within the past two months Post-traumatic headache.
        Patients with diagnosed hypercoagulable states that require chronic treatment with
        warfarin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2011</verification_date>
  <lastchanged_date>January 19, 2011</lastchanged_date>
  <firstreceived_date>January 19, 2011</firstreceived_date>
  <responsible_party>
    <name_title>Clifford Montagnoli VP of Clinical Affairs</name_title>
    <organization>Coherex Medical</organization>
  </responsible_party>
  <keyword>Migraine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
